Dongguk Life Science Achieves Net Profit of 5.1 Billion Won in First Half "Turns to Profit"

[Financial News] Dongguk Life Science announced on the 14th that it recorded a consolidated sales revenue of 69.9 billion won and an operating profit of 6.3 billion won in the first half of this year.
This is an increase of 3.4% in sales and 6.0% in operating profit compared to the same period last year, achieving a net profit of 5.1 billion won and successfully turning to profit.
This strong performance is analyzed to be due to the balanced sales expansion in the contrast agent and 'Medical Equipment & Medical Devices (MEMD)' sectors and the improvement strategy focusing on product mix profitability.
The contrast agent sector saw the number of hospital export cases, which had shrunk after medical disputes, recover to 74% of the previous level, and demand steadily increased through securing new clients, driving performance.
Additionally, by converting existing products to in-house production, cost competitiveness was strengthened, and preparations for the market entry of the new in-house contrast agent product 'Mediray', scheduled for release in the second half, are progressing smoothly.
The MEMD sector secured a stable sales base through the expansion of MRI and CT equipment deliveries and collaboration with large medical examination centers and Lunit AI. Particularly, after the non-insurance conversion of AI-based chest X-rays in April last year, the influx of new clients has been accelerating, and the growth of AI solution sales has been remarkable.
Furthermore, the expansion of new business lineups such as mobile CT and ultrasound AI is also gaining speed.
A representative of Dongguk Life Science said, "The second quarter performance is the result of a strategy centered on in-house products and global technology-based expansion," adding, "In the second half, we will create more visible growth momentum through new product launches, progress in export negotiations, and joint research and development (R&D) achievements with Inventera."


vrdw88@fnnews.com Kang Jung-mo Reporter